智通财经APP获悉，北京天星医疗股份有限公司(简称：天星医疗)于2025年8月26日所递交的港股招股书满6个月，于2026年2月26日失效，递表时中信证券、 建银国际为其联席保荐人。 | 26/08/2025 | 北京天星醫療股份有限公司 | | --- | --- | | | 09/09/2025 整體協調人公告 - 委任（經修訂） 四 | | | 26/08/2025 申請版本（第一次呈交） 全文檔案 [四] 多檔案 | | | 前提交文件: | | | 26/08/2025 整體協調人公告 - 委任 吧 | 据此前招股书，天星医疗是一家专注于运动医学整体临床解决方案的创新型医疗器械公司。据灼识咨询数据，按2024年销售收入计，天星医疗是中国最大的 国产运动医学公司。 截至最后实际可行日期，天星医疗拥有国内最全面的运动医学产品，主要涵盖植入物、有源设备及相关耗材、手术工具等52款产品，可以提供整体临床运动 医学解决方案。第三类医疗器械20款，5款产品在中国市场上所有品牌中首个获批并应用于临床，10款产品在国产品牌中首个获批并应用于临床。此外，天 星医疗在运动医学及智能康复领域的在研产品超过35个。 于往绩 ...

2月6日，赛科希德涨5.1%，截至发稿，报34.59元/股，成交1.50亿元，换手率4.27%，总市值36.71亿 元。赛科希德股价已经连续3天上涨，区间累计涨幅15.55%。 资料显示，北京赛科希德科技股份有限公司位于北京市大兴区百利街19号院，成立日期2003年5月28 日，上市日期2020年8月6日，公司主营业务涉及主要从事血栓与止血体外诊断领域的检测仪器、试剂及 耗材的研发、生产和销售。主营业务收入构成为：试剂53.71%，仪器25.40%，耗材20.58%，其他(补 充)0.31%。 前海开源事件驱动混合A（000423）基金经理为王达。 截至发稿，王达累计任职时间2年335天，现任基金资产总规模7278.43万元，任职期间最佳基金回报 27.88%， 任职期间最差基金回报27.56%。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本 文出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 从基金十大重仓股角度 数据显示，前海开源基金旗下1只基金重仓赛科希德 ...

Core Viewpoint - The Central Cyberspace Administration of China, in collaboration with the National Healthcare Security Administration, is actively addressing false and misleading information related to centralized drug procurement, taking legal actions against accounts that spread anxiety and misinformation [1] Group 1: False Information and Misinformation - Accounts have been identified that fabricate false information regarding the quality of drugs and medical supplies involved in centralized procurement, aiming to attract traffic [1] - Some accounts distort national policies and create false narratives to incite public anxiety regarding original and generic drugs, leading to the promotion of health products and high-end medical insurance [1] - There are instances where non-procurement products are deliberately associated with procurement to mislead the public, damaging the credibility of the procurement process [1]

Financial Data and Key Metrics Changes - Total as-reported revenue grew by 9% in Q3 2026, with constant currency organic revenue growth of 8% driven by volume and a 200 basis points price increase [4] - Gross margin declined by 70 basis points to 43.9%, primarily due to increased tariffs and inflation, despite positive pricing and productivity [4] - EBIT margin decreased by 40 basis points to 22.9% of revenue, mainly due to the decline in gross margin [4] - Adjusted net income from continuing operations was $249.4 million, with earnings per diluted share increasing by 9% to $2.53 [5] - Free cash flow for the first nine months of fiscal 2026 was $736.6 million, showing year-over-year improvement [6] Business Line Data and Key Metrics Changes - Healthcare segment saw constant currency organic revenue growth of 8%, with service growth at 11% and consumables at 8% [7] - Healthcare capital equipment revenue increased by 7%, with backlog remaining over $400 million [7] - AST segment reported constant currency organic revenue growth of 8%, with services growing by 9% and capital equipment revenue increasing by 103% [8] - Life sciences segment experienced a 5% increase in constant currency organic revenue, driven by 11% growth in consumables [8] Market Data and Key Metrics Changes - Orders in the healthcare segment were down 1% year-to-date, facing tough comparisons to the previous year [7] - The backlog in life sciences is showing strong growth, attributed to a recovery in the market compared to a year ago [16] Company Strategy and Development Direction - The company is maintaining its fiscal 2026 outlook, expecting 8%-9% as-reported revenue growth and constant currency organic revenue growth of 7%-8% [9] - The company is focused on mitigating tariff impacts through various strategies, including supplier negotiations and cost reductions [24] - There is a commitment to a more integrated commercial approach in the EMEA region, with structural changes being made to enhance market presence [34] Management's Comments on Operating Environment and Future Outlook - Management expressed caution regarding Q4 growth due to a slowdown in the second half and tough comparisons to last year's strong performance [12][14] - The macro environment appears positive, with no significant downside anticipated for fiscal 2027 [50] Other Important Information - The adjusted effective tax rate for the quarter was 24.2%, a slight decline from the previous year [5] - Capital expenditures for the first nine months totaled $278.8 million, with depreciation and amortization at $363.1 million [6] Q&A Session Summary Question: Insights on Q4 constant currency growth - Management noted a slowdown in the second half and maintained a cautious outlook for Q4, particularly due to tough comparisons from the previous year [12][13] Question: Capital equipment backlog activity - Management indicated stability in healthcare backlog and strong growth in life sciences backlog, attributed to improved market conditions [16] Question: Update on tariff mitigation efforts - Management discussed various mitigation strategies, including shifting product movement and seeking cost reductions [24] Question: Impact of regulatory proposals on supply chain - Management stated that the ASC shift is generally positive, creating new capacity demands, but noted no significant impact from recent regulatory proposals yet [31] Question: Future acquisition plans - Management confirmed ongoing interest in smaller acquisitions but emphasized a disciplined approach to larger transformative deals [44] Question: Cash flow guidance and fluctuations - Management expressed confidence in cash flow guidance but noted potential timing issues in Q4 that could affect collections [48] Question: AST Services growth and market conditions - Management acknowledged a weak start to the quarter but noted improvement by December, attributing some fluctuations to customer inventory adjustments [57][58]

赤天化公告称，预计2025年年度归属于母公司所有者的净利润为 -2.88亿元到 -3.80亿元，将连续亏损。 上年同期净利润为 -8669.35万元。扣非后净利润为 -2.95亿元到 -3.87亿元。医疗服务业务虽营收增约 60%，但药品、耗材无利润且成本高致亏损；煤炭业务因产量低、单价降及计提减值准备亏损；化工业 务因停产大修收入减少、费用增加，净利润同比减少。非经营性损益有净收益348.79万元。 ...

Group 1 - The core business of the company involves the research, production, and sales of medical devices and consumables in the respiratory health field, primarily targeting patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [2] - As of September 30, 2025, the company achieved a revenue of 808 million yuan, representing a year-on-year growth of 34.24%, and a net profit attributable to shareholders of 180 million yuan, with a growth of 43.87% [2] - The company's revenue composition includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [2] Group 2 - As of January 26, 2025, the company's financing balance reached 1.58 billion yuan, with a net financing purchase of 9.44 million yuan on that day [1] - The company has a total of 7,971 shareholders as of September 30, 2025, which is an increase of 16.36% compared to the previous period [3] - The company has distributed a total of 228 million yuan in dividends since its A-share listing [3]

Group 1 - The core stock price of Ruimait rose by 2.02% to 84.97 CNY per share, with a total market capitalization of 7.613 billion CNY as of January 23 [1] - The company experienced a net inflow of main funds amounting to 4.8854 million CNY, with large orders accounting for 20.08% of total purchases [1] - Year-to-date, Ruimait's stock price has decreased by 0.86%, with a 5-day decline of 5.84% and a 20-day increase of 2.99% [2] Group 2 - Ruimait, established on July 27, 2001, specializes in the research, production, and sales of medical devices and consumables in the respiratory health sector, focusing on conditions like obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [2] - The company's revenue composition includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [2] - As of September 30, 2025, Ruimait reported a revenue of 808 million CNY, reflecting a year-on-year growth of 34.24%, and a net profit of 180 million CNY, with a growth of 43.87% [3] Group 3 - Ruimait has distributed a total of 228 million CNY in dividends since its A-share listing [4] - As of September 30, 2025, the number of shareholders increased by 16.36% to 7,971, while the average circulating shares per person decreased by 14.20% to 7,080 shares [3] - Among the top ten circulating shareholders, Huatai-PineBridge Healthcare Mixed Fund is the sixth largest, holding 1.2953 million shares as a new shareholder [4]

Core Points - China donated medical supplies to Burundi's Ministry of Public Health, marking a significant step in bilateral health cooperation [1][3] - The donation ceremony was attended by key officials from both China and Burundi, highlighting the importance of this partnership [1][3] Group 1: Donation Details - The donated medical supplies include over 500 types of medical equipment, pharmaceuticals, and consumables [5] - These supplies will be allocated to three hospitals where Chinese medical teams are stationed [5] Group 2: Historical Context and Future Cooperation - Since 1987, China has been sending medical teams to Burundi, leading to increasingly close cooperation in healthcare [3] - A cataract surgery project named "Bright Action" is set to be implemented in the first half of this year, further enhancing collaboration between the two countries [3]

Core Viewpoint - The stock price of Ruimait has experienced fluctuations, with a recent decline of 2.00% and a total market capitalization of 8.107 billion yuan. The company has seen a net outflow of funds, indicating potential investor caution [1]. Group 1: Stock Performance - Ruimait's stock has increased by 5.57% year-to-date, with a recent decline of 1.16% over the last five trading days. Over the past 20 days, the stock has risen by 6.09%, while it has increased by 3.79% over the last 60 days [2]. - As of January 16, the stock was trading at 90.48 yuan per share, with a trading volume of 50.0166 million yuan and a turnover rate of 0.78% [1]. Group 2: Company Overview - Ruimait Medical Technology Co., Ltd. was established on July 27, 2001, and went public on November 1, 2022. The company specializes in the research, production, and sales of medical devices and consumables in the respiratory health sector [2]. - The company's main business revenue composition includes home respiratory therapy products (64.19%), consumables (32.67%), medical products (3.05%), and others (0.10%) [2]. Group 3: Financial Performance - For the period from January to September 2025, Ruimait achieved an operating income of 808 million yuan, representing a year-on-year growth of 34.24%. The net profit attributable to shareholders was 180 million yuan, reflecting a year-on-year increase of 43.87% [3]. - Since its A-share listing, Ruimait has distributed a total of 228 million yuan in dividends [4]. Group 4: Shareholder Information - As of September 30, 2025, Ruimait had 7,971 shareholders, an increase of 16.36% from the previous period. The average number of circulating shares per person decreased by 14.20% to 7,080 shares [3]. - Among the top ten circulating shareholders, Huatai-PineBridge Healthcare Mixed Fund is the sixth largest, holding 1.2953 million shares as a new shareholder [4].

Core Viewpoint - The newly implemented tax policies aim to support the development of the He Tao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone, facilitating international scientific innovation and collaboration between Shenzhen and Hong Kong [1][2]. Group 1: Tax Policies - The tax policies, effective from February 10, 2026, exempt certain entities within the customs supervision area from import duties, value-added tax, and consumption tax on self-used scientific research goods imported from Hong Kong [1]. - Goods entering the mainland from the customs supervision area will require the payment of import taxes, but those already taxed in the customs supervision area will not incur additional taxes [1][2]. Group 2: Goods and Benefits - The first batch of goods eligible for tax exemption includes 509 items across six categories, such as equipment, consumables, and biological samples, which will help reduce costs for innovation entities [2]. - The policies are expected to enhance cooperation between Shenzhen and Hong Kong, promoting technological innovation and industrial development, and supporting Hong Kong's integration into the national development framework [2]. Group 3: Regulatory Framework - The He Tao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone is the only major cooperation platform focused on technological innovation within the Guangdong-Hong Kong-Macao Greater Bay Area [3]. - The upcoming implementation of the Shenzhen Economic Special Zone regulations will establish a unique regulatory model that simplifies customs processes and supports cross-border scientific activities [3].